| 51 |
26562035 | Platelet aggregation in response to ADP is highly variable in normal donors and patients on anti-platelet medication. | 2016 Jul 1 |
1 |
| 52 |
26581884 | Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial. | 2016 Jan |
1 |
| 53 |
26639039 | Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). | 2016 Jan 15 |
1 |
| 54 |
26743169 | Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. | 2016 Mar |
1 |
| 55 |
26995378 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. | 2016 Apr |
1 |
| 56 |
27423939 | The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. | 2016 Aug |
1 |
| 57 |
27586412 | P2Y12 Receptor Antagonists and Morphine: A Dangerous Liaison? | 2016 Sep |
1 |
| 58 |
27740874 | Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. | 2016 Dec |
1 |
| 59 |
27959713 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. | 2016 Dec 22 |
1 |
| 60 |
24433337 | Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. | 2015 |
1 |
| 61 |
25744739 | Dual antiplatelet therapy for coronary artery disease. | 2015 |
1 |
| 62 |
25777663 | Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. | 2015 Jul 18 |
1 |
| 63 |
25778862 | Association of P2RY12 polymorphisms with eosinophil and platelet activation in patients with aspirin-exacerbated respiratory disease. | 2015 May |
1 |
| 64 |
26224244 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? | 2015 |
1 |
| 65 |
24309957 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. | 2014 Feb |
2 |
| 66 |
24529662 | How to manage prasugrel and ticagrelor in daily practice. | 2014 Mar |
1 |
| 67 |
25123696 | Cangrelor: a novel intravenous antiplatelet agent with a questionable future. | 2014 Oct |
1 |
| 68 |
25524333 | Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. | 2014 Dec 23 |
1 |
| 69 |
29805889 | Association Between the P2RY12 Receptor Gene Polymorphism and Aspirin Resistance in Patients with Coronary Artery Disease. | 2014 |
3 |
| 70 |
23666308 | [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents]. | 2013 Mar |
1 |
| 71 |
23751937 | Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. | 2013 Sep 1 |
1 |
| 72 |
23777967 | [Clopidogrel plus acetylsalicylic acid: a deadly combination]. | 2013 |
1 |
| 73 |
23884248 | Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. | 2013 Oct |
1 |
| 74 |
24093982 | P2Y12 inhibitors in acute coronary syndromes: which and when? | 2013 Mar-Apr |
1 |
| 75 |
22574824 | P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. | 2012 Oct |
1 |
| 76 |
20966167 | The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. | 2011 Feb 17 |
1 |
| 77 |
21189314 | What is the best dose of aspirin in association with P2Y12 antagonists? | 2011 Feb |
1 |
| 78 |
21479342 | Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. | 2011 May |
2 |
| 79 |
21554368 | P2Y12 receptor gene mutation associated with postoperative hemorrhage in a Greater Swiss Mountain dog. | 2011 Jun |
1 |
| 80 |
21812912 | Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. | 2011 Oct |
1 |
| 81 |
20094648 | Limitations of current therapies to prevent thrombosis: a need for novel strategies. | 2010 Feb |
1 |
| 82 |
20597033 | P2Y(12) antagonists as antiplatelet agents - Recent developments. | 2010 Jul |
1 |
| 83 |
19249429 | Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. | 2009 Mar |
1 |
| 84 |
19882081 | P2Y12 inhibitors: thienopyridines and direct oral inhibitors. | 2009 Nov |
1 |
| 85 |
20008209 | Antiplatelet agents. | 2009 |
1 |
| 86 |
20040278 | Frontiers in platelet inhibition. | 2009 Dec |
1 |
| 87 |
17995973 | P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. | 2008 Apr |
1 |
| 88 |
18506123 | Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? | 2008 Jun |
1 |
| 89 |
17531573 | Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. | 2007 Jun 1 |
1 |
| 90 |
16476694 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. | 2006 May |
1 |
| 91 |
12913786 | Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. | 2003 Sep |
1 |